Suchergebnisse - (Person:"Curtin, Nicola")

PubPharm (12)

1

PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS

enthalten in: NMR in biomedicine | 2017

von Almeida, G. | Bawn, C. | Galler, M. | +6

2

Strategies Employed for the Development of PARP Inhibitors

enthalten in: Methods in molecular biology (Clifton, N.J.) | 2017

von Canan, S. | Maegley, K. | Curtin, N.

3

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

enthalten in: British journal of cancer | 2016

von Drew, Y. | Ledermann, J. | Hall, G. | +14

CommentIn: Br J Cancer. 2016 Mar 29;114(7):713-5. - PMID 27022824

4

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

enthalten in: Molecular cancer therapeutics | 2015

von Parrish, K. | Cen, L. | Murray, J. | +11

5

PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib

enthalten in: Clinical pharmacology in drug development | 2015

von Wang, D. | Li, C. | Sun, W. | +7

6

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

enthalten in: Cancer chemotherapy and pharmacology | 2013

von Plummer, R. | Lorigan, P. | Steven, N. | +10

7

The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice

enthalten in: Molecular cancer therapeutics | 2011

von Ali, M. | Kamjoo, M. | Thomas, H. | +6

8

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition

enthalten in: Nature medicine | 2011

von Johnson, N. | Li, Y. | Walton, Z. | +12

CommentIn: Nat Rev Clin Oncol. 2011 Sep;8(9):508. - PMID 21769119

9

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2

enthalten in: Journal of the National Cancer Institute | 2011

von Drew, Y. | Mulligan, E. | Vong, W. | +9

10

Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2010

von Mukhopadhyay, A. | Elattar, A. | Cerbinskaite, A. | +7